Objective: To evaluate the outcomes one-year and longer following stereotactic laser amygdalohippocampotomy for mesial temporal lobe epilepsy in a large series of patients treated over a five-year period since introduction of this novel technique.
Methods: Surgical outcomes of a consecutive series of fifty-eight patients with mesial temporal lobe epilepsy who underwent the surgery at our institution with at least 12-months follow-up were retrospectively evaluated. A subgroup analysis was performed comparing patients with and without mesial temporal sclerosis.
Results: One-year following stereotactic laser amygdalohippocampotomy 53.4% (95% confidence interval: 40.8%-65.7%) of all patients were free of disabling seizures (Engel 1). Three of nine patients became seizure free following repeat ablation. Subgroup analysis showed that 60.5% (95% confidence interval: 45.6%-73.7%) of patients with mesial temporal sclerosis were free of disabling seizures as compared to 33.3% (95% confidence interval: 15.0%-58.5%) of patients without mesial temporal sclerosis. Quality of Life in Epilepsy-31 scores significantly improved at the group level, few procedure-related complications were observed, and verbal memory outcome was better than historical open resection data.
Interpretation: In an unselected consecutive series of patients, stereotactic laser amygdalohippocampotomy yielded seizure-free rates for patients with mesial temporal lobe epilepsy lower than, but comparable to, the outcomes typically associated with open temporal lobe surgery. Analogous to results from open surgery, patients without mesial temporal sclerosis fared less well. This novel procedure is an effective minimally invasive alternative to resective surgery. In the minority of patients not free of disabling seizures, laser ablation presents no barrier to additional open surgery. This article is protected by copyright. All rights reserved.